How should the dose of Ceftum (Cefuroxime) be adjusted in patients with impaired renal function, specifically Chronic Kidney Disease (CKD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftum (Cefuroxime) Dose Adjustment in CKD

Cefuroxime requires mandatory dose reduction in patients with chronic kidney disease based on creatinine clearance, with specific adjustments outlined in the FDA labeling that must be followed to prevent drug accumulation and toxicity. 1

Dose Adjustment Algorithm

The FDA-approved dosing regimen for cefuroxime in renal impairment is stratified by creatinine clearance (CrCl) 1:

Standard Dosing by Renal Function:

  • CrCl >20 mL/min: 750 mg to 1.5 grams every 8 hours (no adjustment needed) 1

  • CrCl 10-20 mL/min: 750 mg every 12 hours (extend interval) 1

  • CrCl <10 mL/min: 750 mg every 24 hours 1

  • Hemodialysis patients: Give supplemental 750 mg dose after each dialysis session 1

Critical Implementation Points

Calculating Creatinine Clearance:

The Cockcroft-Gault formula should be used for dose adjustments, as this is what drug labeling and clinical studies are based on 1, 2. The formula accounts for age, weight, and sex 1:

  • Males: CrCl (mL/min) = [Weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)] 1
  • Females: 0.85 × male value 1

Pharmacokinetic Rationale:

Cefuroxime is primarily eliminated by glomerular filtration without significant metabolism 3, 4. In renal impairment, the elimination half-life increases substantially, leading to drug accumulation if doses are not adjusted 4, 5. The dosing strategy extends the interval between doses rather than reducing the dose amount, which helps maintain adequate peak concentrations for bactericidal activity 1.

Monitoring Requirements

Renal function should be monitored during therapy, especially in seriously ill patients receiving maximum doses 1. Key monitoring parameters include:

  • Serum creatinine to assess stable renal function before calculating CrCl 1
  • Clinical response and signs of drug accumulation 1
  • Evaluation for superinfection with prolonged use 1

Special Populations and Precautions

Elderly Patients:

Elderly patients (>59 years) are at higher risk of drug toxicity due to age-related decline in renal function 6. The Cockcroft-Gault formula automatically adjusts for age, but additional clinical vigilance is warranted 1.

Dialysis Considerations:

  • Hemodialysis: Cefuroxime is dialyzable, requiring a supplemental dose after each dialysis session 1, 3
  • Peritoneal dialysis: For chronic peritoneal dialysis, a loading dose of 10 mg/kg followed by 5 mg/kg into each dialysis cavity has been used for similar cephalosporins 3

Concurrent Nephrotoxic Medications:

Cephalosporins should be given cautiously with potent diuretics or aminoglycosides, as these combinations may adversely affect renal function 1. Nephrotoxicity has been reported with concomitant aminoglycoside use 1.

Common Pitfalls to Avoid

  • Do not use reduced doses without extending intervals - this compromises bactericidal activity 1
  • Do not use MDRD or CKD-EPI formulas for dosing - drug labeling is based on Cockcroft-Gault 1, 2
  • Do not forget post-dialysis supplementation - failure to replace dialyzed drug leads to subtherapeutic levels 1
  • Do not assume stable renal function - serum creatinine should represent steady-state before calculating CrCl 1

Duration of Therapy

Continue therapy for a minimum of 48-72 hours after the patient becomes asymptomatic or bacterial eradication is documented 1. For streptococcal infections, a minimum of 10 days is required to prevent rheumatic fever or glomerulonephritis 1.

References

Research

[Pharmacokinetics of ceftazidime in healthy and renal failure subjects].

Presse medicale (Paris, France : 1983), 1988

Research

Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

European journal of clinical pharmacology, 2009

Research

Dosage adjustment for ceftazidime in patients with impaired renal function.

European journal of clinical pharmacology, 1986

Guideline

Augmentin Safety in Patients with Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.